Latest Headlines

Latest Headlines

Eisai doubling its Indian API to ride Japan's generic wave

Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own India-made APIs to competitors. It is doubling its API production to have the extra product for sale in Japan.

Japan's Eisai surprises with API move

Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh. 

Bristol-Myers, Pfizer and Eisai bet big biobucks on the Japanese market

Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced to the point where surgery is not an option.

Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use.

Japanese drugmakers shift focus as government pushes for more generics

Top Japanese drugmakers are moving to sell off their noncore businesses and less profitable generic drugs to focus on new drugs that are protected by patents and that bring in millions more in revenue.

The biggest winners--and losers--in the 2015 race for new drug approvals

In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. Now, here's the full list of new drugs approved by the FDA in 2015, in chronological order.

Struggling Eisai looks for help in China with new generics deal

Eisai's had a rough few years, but it's predicted an upswing in operating profit in the not-too-distant future. And to help it get there, it's struck a new deal in China.

Eisai pairs up with a French research shop to find new cancer drugs

Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.

UPDATED: Biogen's manufacturing feels the pain of its cost-cutting

Biogen has been adding significantly to its manufacturing network lately. Now, it has decided, it is time to subtract.